Sugi Predict

Sugi Predict / Compounds / SCHEMBL9542940

SCHEMBL9542940

SCHEMBL9542940

CC(C)(C)OC(=O)N1C[C@@H](Cc2ccccc2)C[C@@H]1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.48
▸ NR1H3 Q13133 2/20 0.48
▸ AGTR2 P50052 9/20 0.46
▸ ACE P12821 1/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ KLK7 P49862 2/20 0.42
▸ STS P08842 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ KLK5 Q9Y337 1/20 0.42
▸ MCL1 Q07820 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7285245 1.00 NR1H2 (0.48) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL13687997 1.00 NR1H2 (0.48) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL21409001 1.00 NR1H2 (0.48) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL6183348 1.00 NR1H2 (0.48) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL1373084 1.00 NR1H2 (0.48) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL6183345 1.00 NR1H2 (0.48) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL30882690 0.95 NR1H2 (0.45) NR1H2NR1H3AGTR2ACEJAK2
SCHEMBL1371521 0.90 CYP2C19 (0.44) NR1H2NR1H3ACEMCL1
SCHEMBL27190612 0.90 CYP2C19 (0.44) NR1H2NR1H3ACEMCL1
SCHEMBL2171522 0.90 CYP2C19 (0.44) NR1H2NR1H3ACEMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 — — US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 — — US disclosed
US-12486278-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-12-02 — — US disclosed
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-24 — — US disclosed
CN-119350433-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2025-01-24 — — CN disclosed
US-12195427-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-01-14 — — US disclosed
CN-112867706-B MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-11-15 — — CN disclosed
CN-118373875-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-07-23 — — CN disclosed
CN-117964683-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-05-03 — — CN disclosed
CN-117964684-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-05-03 — — CN disclosed
US-20240092788-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2024-03-21 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 — — US disclosed
CN-115103709-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2022-09-23 — — CN disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
WO-1993020099-A2 CCK AND/OR GASTRIN RECEPTOR LIGANDS FERRING B.V. (NL) 1993-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NR1H2 4695/4885NR1H3 4742/4885AGTR2 192/4885
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 NR1H2 4644/4885NR1H3 4712/4885AGTR2 183/4885
US-12486278-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 NR1H2 4695/4885NR1H3 4742/4885AGTR2 192/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 NR1H2 4695/4885NR1H3 4742/4885AGTR2 192/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NR1H2 4644/4885NR1H3 4712/4885AGTR2 183/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NR1H2 4644/4885NR1H3 4712/4885AGTR2 183/4885
US-12195427-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 NR1H2 4644/4885NR1H3 4712/4885AGTR2 183/4885
US-20240092788-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NR1H2 4695/4885NR1H3 4742/4885AGTR2 192/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NR1H2 4567/4885NR1H3 4660/4885AGTR2 130/4885
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NR1H2 4644/4885NR1H3 4712/4885AGTR2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.